Table 2.
Baseline characteristics compared between groups after propensity score matching.
| Variable | Total (N = 56) | HIV-positive group (n = 37) | HIV-negative group (n = 19) | p-value |
|---|---|---|---|---|
| Age | 61.9 ± 8.3 | 61.2 ± 7.8 | 63.1 ± 9.1 | 0.430 |
| Sex | ||||
| Male | 47 | 31 | 16 | 0.967 |
| Female | 9 | 6 | 3 | |
| Tumor type | ||||
| Lung cancer | 27 | 17 | 10 | 0.890 |
| Liver cancer | 19 | 13 | 6 | |
| Gastric cancer | 10 | 7 | 3 | |
| Cancer stage | ||||
| I–III | 33 | 21 | 12 | 0.645 |
| IV | 23 | 16 | 7 | |
| PD-1 inhibitor | ||||
| Tislelizumab | 19 | 13 | 6 | 0.919 |
| Camrelizumab | 24 | 16 | 8 | |
| Sintilimab | 13 | 8 | 5 | |
| Treatment line | ||||
| First | 40 | 26 | 14 | 0.789 |
| Second or above | 16 | 11 | 5 | |
| Cycles | 7.00 | 7.00 | 6.00 | 0.882 |